Rebound was defined as a PASI of $125% from baseline or new generalized pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of therapy discontinuation. A relapse was defined as a 50% loss of the maximum PASI improvement from baseline. 2, 3 In total, 139 patients in our department received brodalumab. All patients relapsed after a variable period of treatment discontinuation. Thirty patients received secukinumab after discontinuation of brodalumab and were included in the analysis. The remaining patients were successfully treated with methotrexate, antietumor necrosis factor antibodies, or ustekinumab. The mean treatment duration with brodalumab was 160 (range 24-240) weeks. PASI 90 (ie, a 90% improvement from baseline PASI) was obtained in all these patients before drug discontinuation. The mean duration between brodalumab discontinuation and psoriasis relapse was 9 (range 2-24) weeks. The characteristics of the population are summarized in Table I . Of note, the severity of psoriasis after discontinuation of brodalumab was higher than the severity at baseline ( Table I ). The mean time lapse between brodalumab discontinuation and secukinumab treatment was 10 (range 2-12) months. Twenty-six patients received 1 or multiple serial systemic treatments in an attempt to control the psoriasis relapse before introducing secukinumab. These intermediate treatments failed to result in PASI 75. No patient or clinical characteristics could be identified that could distinguish between the population who was successfully treated with other systemic treatments and the 26 patients who were not. The mean PASI decreased from 36.9 (range 18-68.4) to 0.74 (range 0-9.6) at 9 weeks after secukinumab treatment and to 0.23 (range 0-5) at 36 weeks (range 9-96; Fig 1) after secukinumab treatment. At 9 weeks, all the patients achieved a PSA clear score according to the American College of Rheumatology criteria. Nine of the 13 patients were followed up for 36 weeks and were PSA clear. The side effects of secukinumab included oral candidiasis (4/30) and upper respiratory tract infection (1/30). No other infectious or allergic reactions were observed.
Abrupt discontinuation of a treatment despite good clinical efficacy is regularly observed in clinical practice in patients who are undergoing surgery, have an active infection, become pregnant, or go on extensive travel to areas where such treatment is not available or simply for personal convenience. The transient but necessary discontinuation of brodalumab treatment due to a safety issue offered us a unique opportunity to study a large and homogeneous group of patients, including the clinical follow-up of their disease and their response to treatment after relapse or rebound. Our results suggest that secukinumab (an IL-17A inhibitor) is effective for severe forms of psoriasis relapse and rebound after abrupt discontinuation of brodalumab (an IL-17 receptor inhibitor).
We are in debt to Meri Tulic for editing the manuscript. However, it is also important to examine the use of apremilast in real-world settings. The purpose of this study was to determine the failure rate and drug survival of apremilast in clinical practice. This retrospective chart review included patients who sought treatment at the dermatology clinic Kaiser Permanente Los Angeles Medical Center, were given a psoriasis diagnosis by a dermatologist, and were treated with apremilast 30 mg twice daily with standard introductory dosing during January 1, 2015-January 11, 2018. A total of 84 patients were included in the study. Treatment failure was defined as the need to add either an oral medication (eg, methotrexate, cyclosporine, or acitretin) or phototherapy or switch to a different oral or biologic agent. The date of failure was set as the visit date at which the therapy was altered. Kaplan-Meier methodology was used to calculate probability of drug survival in the entire cohort ( persistence and loss to follow-up groups were censored) and provide comprehensive survival duration.
Our results showed that 50.0% (40/80) of patients remained on apremilast at the end of the study, with treatment durations ranging 45-1004 days (Fig 1) . The therapy for the remaining patients 50.0% (40/80) failed after an average of 198 days and median of 141 days of treatment. Three patients were lost to follow-up. Mean drug survival duration (Fig 2) was 348 (95% confidence interval 275-420) days. Median drug survival was 295 days.
While clinical trials have examined the safety and efficacy of apremilast for 52 weeks, 3 this study examines drug survival over a longer period of time in a real-world setting. The results of this study suggest a higher discontinuation rate compared with a previous study by Mayba et al, 4 which reported 16.1% (18/99) of patients stopped apremilast treatment during their study period. However, their cohort also included patients taking apremilast with other systemic medications, which could have affected persistence rates of apremilast.
Despite a relatively short study duration and a small sample size, this study offers important information regarding response durations in real-world practice. In addition, this study does not address the clinical efficacy of apremilast. The results from this study demonstrate that persistence rates appear to be similar among patients who had previously tried other systemics (48%) and those who had not (53%). Which supports the utility of apremilast as both a potential transition from topical to systemic medications and for those who have previously failed other systemic medications. While apremilast provides a nonbiologic treatment option with a favorable safety profile, some patients might eventually require additional therapy. Future studies with longer study durations and larger sample sizes would enhance generalizability of results to decision-making in clinical practice.
